Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Features

1265 Features
Sankyo and Daiichi plans show Japanese consolidation goes on

04 Mar 05

Sankyo and Daiichi Pharmaceutical are considering merging in October 2005 to become Japan's number two drugmaker, as competition in the market continues to intensify. Following the announcement of mergers between Yamanouchi and Fujisawa, and Dainippon and Sumitomo, will continuous domestic consolidation ensure a place for global integration in the face of western pressure?
Datamonitor

Bipolar Disorder

03 Mar 05

Bipolar affective disorder – previously referred to as manic depression – is a psychiatric disorder affecting at least 1% of the UK population, and depending on the definition used, may affect as many as 5% of the population. A recent World Health Organization analysis of the major global causes of disability, economic and social burden, indicated that bipolar affective disorders are ranked in the top ten, and account for 2.5% of total years lost to disability across all age groups.
CSF Medical Communications

Emerging oncology treatments: A focus on targeted therapeutics, supergeneric reformulations and supportive care

02 Mar 05

The oncology market is the third largest pharmaceutical market, behind the cardiovascular and CNS therapy areas, and is currently experiencing strong growth. Worth an estimated $35 billion in 2003, analysts predict that the sector will grow to $60 billion by 2010, yielding a compound annual growth rate of 8% over this period. Major changes are however occurring in the oncology market. Cytotoxics, a cornerstone of oncology, are reaching patent expiry and the last cytotoxic genericization is expec
LeadDiscovery

Blockbuster brands generate generic goals

25 Feb 05

Despite being the current gold standard and sales heavyweight of the antipsychotic market with $4 billion in global sales, Eli Lilly's Zyprexa (olanzapine) is facing legal action in the US over alleged side effects. Along with other blockbuster drugs in the market, it may also run into intense competition from generics earlier than expected, according to new research from Datamonitor.
Datamonitor

Emerging treatments for inflammatory bowel disease (IBD)

20 Feb 05

Ulcerative colitis and Crohn’s disease, known collectively as inflammatory bowel disease (IBD) currently affects 0.5-1% of the Western world’s population. This translates to over one million people in America (525,000 Ulcerative Colitis, 490,000 Crohn's Disease) and four million people worldwide. Sufferers experience a range of gastrointestinal symptoms, including diarrhea, rectal bleeding and abdominal pain resulting in weight loss as well as other extraintestinal manifestation such as skin and
LeadDiscovery

Migraine treatment - a financial headache

18 Feb 05

More than 70 million people worldwide suffer from migraines, yet despite the dramatic effects on everyday life that migraine sufferers face, new research from Datamonitor has revealed that due to economic constraints within national healthcare systems, some patients aren't getting the best available treatment.
Datamonitor

Alzheimer’s Disease

15 Feb 05

Dementia currently affects over 750,000 people in the UK, with 650,000 new cases arising each year across the European Union. Alzheimer’s disease is the major cause of dementia and accounts for about 55% of all cases. It is a progressive, degenerative disease which affects memory, judgement, orientation, behaviour and language skills, and can place an enormous stress on family caregivers, 49% of whom are over 70 years of age.
CSF Medical Communications

InterMune's hepatitis strategy gets the right response

11 Feb 05

A significant rise in sales of InterMune's hepatitis drug Infergen, from $9.3 million in 2003 to $22.3 million in 2004, is the result of the company's focus on marketing Infergen to HCV non-responders. In targeting this vital patient sub-group, InterMune could gain a useful head start in an area of hepatitis treatment that is set to become fiercely competitive in the years ahead.
Datamonitor

Atopic Eczema

08 Feb 05

Atopic eczema (or atopic dermatitis) is the most common chronic skin disease in childhood, and it can have a significant impact on the lives of patients and their families. New and effective treatments have been introduced in recent years, and it has been postulated that good control of atopic eczema with these agents may also reduce the incidence and severity of asthma.
CSF Medical Communications

Asthma: alternative anti-inflammatory agents needed for patient subgroup

04 Feb 05

Five million adult asthmatics may have predominantly neutrophilic inflammation. Whilst this phenotype is usually associated with severe asthma, it may be more prevalent across the range of disease severities than originally thought. The emergence of this phenotype in asthma raises important implications for treatment practice.
Datamonitor

Eisai's retinoic acid (RAR)-alpha receptor agonist as a candidate therapy for the treatment of lupus nephritis

03 Feb 05

Lupus is a chronic inflammatory disease that can affect various parts of the body, especially the skin, joints, blood, and kidneys. For most people, lupus is a mild disease affecting only a few organs. For others, it may cause serious and even life-threatening problems. In particular lupus nephritis claim a significant number of lives. More than 16,000 Americans develop lupus each year. It is estimated that 500,000 to 1.5 million Americans have been diagnosed with lupus. Current treatments focus
LeadDiscovery

Free Sales Force Effectiveness industry trends report.

27 Jan 05

Get your hands on this unique free intelligence from eyeforpharma's recent Sales Force Effectiveness conferences in Europe and the USA.
Selma Nawaz

Progress in the treatment of peripheral arterial disease (PAD)

27 Jan 05

In contrast to coronary and cerebral artery disease, peripheral arterial disease (PAD) remains an under-appreciated condition that despite being serious and extremely prevalent is rarely diagnosed and even less frequently treated. This situation is now changing as physician awareness grows in parallel with increased use of existing therapeutics and the development of improved cardiovascular agents, gene therapies and devices
LeadDiscovery

Migraine

24 Jan 05

For people with migraine, today’s world is a better world than the one their parents knew. The last 15 years have seen major advances, giving us not only a much clearer understanding of the disorder but also considerably more effective therapies. Treatments exist that – if made available and used in the right way – can substantially relieve the majority of people affected by migraine.
CSF Medical

High Incidence of surgical site infections in Europe presents a risk to patients, and an economic burden

21 Jan 05

The increasing incidence of surgical site infections (SSIs) among hospital patients in Europe has led to a call to action for cost-effective preventative measures to be put in place by hospitals, to help minimize the risk of infection and the cost impact on healthcare systems. A consensus paper, developed by a number of leading healthcare experts in Europe and published today in the International Wound Journal, indicates the scale of the problem and the estimated financial impact on the health
Wound Healing Research Unit

INC RESEARCH MOVES INTO NEW EUROPEAN HEADQUARTERS

20 Jan 05

INC RESEARCH MOVES INTO NEW EUROPEAN HEADQUARTERS TO ACCOMMODATE CONTINUING GLOBAL EXPANSION
Kevan Nicholson

Epilepsy

17 Jan 05

Epilepsy is a common condition in the UK, with an incidence of approximately 80 cases per 100,000 population per year, and a prevalence of 5–10 cases per 1000. Yet, despite this high prevalence, it remains a stigmatising condition, with occupational and social disadvantages imposed on the individual. Epilepsy is difficult to diagnose, requiring a detailed history, and is complex to manage.
Csf Medical Communications

siRNA Strategies

17 Jan 05

Knowledge will be pooled and ideas investigated through focused discussion topics: * What approach to take to target validation? * Establishing the true impact of off-target effects * Unravelling the different pathways * What can delivery systems achieve? * What are the pros and cons of different chemical modification? * Addressing pharmacokinetics and modification issues for each disease What do I need for clinical testing of an siRNA compound?
Charlotte Hayes

Addressing the unmet need of diabetics with new generation non-insulin antidiabetics

17 Jan 05

It is estimated that there are more than 38 million people in the seven major markets with diabetes and this figure is set to rise to 50 million in 2012. However, despite this vast potential patient population, low diagnosis rates, the chronic nature of the disease, the need for combination therapy, the lack of an oral antidiabetic agent offering effective long-term therapy and the association of injectable therapies with poor patient compliance mean that a broad spectrum of unmet needs exists.
LeadDiscovery

Morgan Levy (formally E-Focus Resourcing) has rebranded.

13 Jan 05

Morgan Levy (formally E-Focus Resourcing) has pleasure in announcing that we have re-branded to Morgan Levy with effect from January 2005.
GARY M BRITNELL

SOCS1 silencing dramatically increases the anti-cancer efficacy of dendritic cell vaccines

04 Jan 05

The development of dendritic cell vaccines to fight cancer is an attractive therapeutic approach. Usually this strategy involves pre-pulsing dendritic cells with cancer antigen and maturing them ex vivo prior to administering them to patients. Limitations to this approach include the cumbersome nature of antigen loading and maturation and the limited immunogenicity of the cells. The company BioVEX have successfully developed viruses to load dendritic cells with antigen. Researchers from Baylor h
LeadDiscovery

Sorafenib offers hope in the battle for liver cancer survival

20 Dec 04

The outlook for hepatocellular carcinoma (HCC) sufferers is bleak - current medication has a five-year survival rate for those with liver cancer of less than 5% in the developed world and even lower in developing countries. However, patients in trials of a new drug called Sorafenib have seen their survival times double. Datamonitor's Dr Lorna Fern investigates...
Datamonitor

Fulfilling a Millennium Healthcare Promise

15 Dec 04

Despite the advances made in healthcare there remains a startling amount of the world’s population that is unable to gain access to even the most basic services and treatments. This is an issue that has attracted considerable media coverage and represents a challenge for all those involved in healthcare to overcome.
Dr Faiz Kermani

“Get behind Clean Hospital Summit” call as patient pressure rises

14 Dec 04

Britain’s hospital patients, led by Claire Rayner, today called for healthcare professionals to get behind the UK’s first ever Clean Hospitals Summit, planned for April 14-15, 2005.
Anna Harris/ Alan Murray

Developments in oncolytic viruses - An emerging approach to cancer therapeutics

13 Dec 04

This report introduces the emerging field of oncolytic viruses and the various benefits that oncolytic virology can offer in the treatment of cancer. Clinical data suggest that oncolytic viruses may offer therapeutic advantages over existing cancer therapies such as chemotherapy and radiation and may even act synergistically with these conventional approaches. This report evaluates preclinical and clinical data on oncolytic viruses that have entered the clinic.
LeadDiscovery

Japanese Pharma Prepares to Bounce Back

13 Dec 04

The Japanese pharmaceutical industry is facing a range of problems in competing with its foreign rivals. However, it has survived tough operating conditions before and there are signs that it will do so again.
Dr Faiz Kermani

Serevent warning focuses attention on the need for combination therapy

10 Dec 04

The recent announcement by the FDA's associate director for science and medicine that sales of GlaxoSmithKline's asthma drug Serevent should be restricted, or halted, led to an estimated 3.8% fall in the company's share price. However, Datamonitor's Laura Harris comments that, with Seretide accounting for the majority of GSK's asthma sales, the panic may be premature.
Datamonitor

Drug Discovery Technology Europe 2005

09 Dec 04

Distinct, original scientific and business content focusing on R&D productivity presented by an international line-up of industry experts. Drug Discovery Technology® Europe is known for its high standard of speakers and coherent case studies, which guarantee that delegates grasp an understanding of the pressing issues that affect their industry. This year, for the first time, the conference will be co-located with two other events, InfoTechPharma® 2005 and PharmaSolutions Expo.
Charlotte Hayes

InfoTechPharma 2005

09 Dec 04

The premier annual global forum for top-level Pharma IT executives, examining innovative IT systems and applications to support and accelerate R&D. This exciting programme is the result of research with well over 100 industry professionals and the InfoTechPharma® scientific advisory board. The programme contains only original content tackling key subjects that are currently impacting R&D in pharma and biotech. The format of this years conference will provide an environment that will facilitate i
Charlotte Hayes

PharmaSolutions Expo

09 Dec 04

PharmaSolutions Expo is a unique event gathering the drug discovery, drug development and informatics communities under one roof. Meet face-to-face with solution providers and make comparisons of new technologies. This exhibition will showcase the latest tools and solutions for R&D scientists and Pharma IT professionals. Free exhibition features include: dedicated poster areas and “meet the author” poster sessions, free seminars, lunchtime roundtable discussion groups, biotech start-up presentat
Charlotte Hayes

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.